NCIC CLINICAL TRIALS GROUP

LUNG

DISEASE SITE COMMITTEE MEETING

AGENDA

Delta Chelsea Hotel, Toronto, Ontario
Saturday, May 3, 2008 - 8:30 am – 4:15 pm (EST)
Room: Churchill A

Chair: Frances Shepherd

8:30 am  WELCOME AND ANNOUNCEMENTS
          Dr. F. Shepherd

8:35 am  SUB-COMMITTEE REPORTS
          Small Cell         Dr. P. Ellis
          Radiation        Dr. Y. Ung
          Mesothelioma and Thymoma  Dr. C. Lee
          Correlative Sciences  Dr. M-S Tsao

9:15 am  NON-SMALL CELL LUNG CANCER
          Surgical Adjuvant and Neoadjuvant and Locally Advanced Trials
          BR.16 - Randomized placebo controlled trial of adjuvant selenium in completely resected stage I NSCLC (ECOG)
          DR. T. Waddell
          BR.19 - Randomized trial of adjuvant gefitinib versus placebo after complete resection of Stage IB, II IIIA NSCLC
          DR. G. Goss
          BRC.2 - ECOG 1505 Randomized trial of chemotherapy +/- bevacizumab in completely resected Stage IB-IIIA NSCLC
          DR. C. Butts
          BRC.2 - ECOG 1505 Randomized trial of chemotherapy +/- bevacizumab in completely resected Stage IB-IIIA NSCLC
          ECONOMIC ANALYSIS
          BR.5 - CALGB 140503 A Phase III randomized trial of lobectomy versus sub-lobar resection for small (<2cm) peripheral NSCLC
          DR. J. Deslauriers
          BR.27 - LUNG-ART Post-operative adjuvant radiation for completely resected N2 NSCLC
          DR. Yee Ung

10:30 am  Coffee Break (~15 min)

11:15 am  Advanced NSCLC
          BR.24 - Randomized trial of paclitaxel and carboplatin +/- AZD 2171 in advanced Non-SCLC
          DR. S. Laurie
BRC.4 -N0723  A Phase III biomarker validation study of second-line therapy in patients with advanced NSCLC randomized to pemetrexed versus erlotinib  
Dr. G. Liu

11:45 am  SMALL CELL LUNG CANCER
BR.28 CONVERT – Once daily versus twice daily radiation for limited SCLC  
Dr. A. Bezjak

12:00 pm  Lunch (90 min.)

1:30 pm  IND STUDIES
IND.183 - Phase II trial of sutent in 2nd-line treatment of malignant mesothelioma  
Dr. S. Laurie
IND.190 – Phase I-II trial of etoposide/cisplatin + MK-0646 in extensive stage SCLC  
Dr. P. Ellis
Report from the IND Committee  
Dr. G. Goss

2:30 pm  RADIOThERAPY STUDIES
BR.25 - Hypofractionated radiotherapy for medically inoperable NSCLC  
Dr. P. Cheung
BRC.1 - PCI in Non-SCLC  
Dr. A. Sun
RTOG - PCI in SCLC  
Dr. A. Sun

3:00 pm  Coffee break (~15 min)

3:15 pm  ECONOMIC AND DATA-BASE ANALYSES OF LUNG TRIALS
Economic analyses active and planned  
Dr. N. Leighl
Database analyses  
Dr. F. Shepherd

3:45 pm  POTENTIAL NEW TRIALS UNDER CONSIDERATION
Potential trials in previously treated NSCLC  
Dr. F. Shepherd
Etoposide/cisplatin/XRT + PI-3 Kinase inhibitor  
Dr. F. Shepherd
Phase I-II in limited SCLC  
Dr. Y. Ung
Nimotuzumab + XRT in medically inoperable peripheral NSCLC